Supernus Pharmaceuticals (NASDAQ:SUPN) has witnessed a drop of 8% or 229,962 shares in its short figure. The short interest diminution took it from 2,869,377 on May 31,2016 to 2,639,415 on June 15,2016. In terms of floated shares, the short interest was calculated to be 5.6%. The days to cover are 6 given that the daily volume averaged 432,801 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Supernus Pharmaceuticals (NASDAQ:SUPN): The stock opened at $18.35 on Friday but the bulls could not build on the opening and the stock topped out at $18.86 for the day. The stock traded down to $17.93 during the day, due to lack of any buying support eventually closed down at $18.44 with a loss of -3.56% for the day. The stock had closed at $19.12 on the previous day. The total traded volume was 2,080,044 shares.
The company shares have rallied 12.92% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $23.30 and the one year low was seen on Feb 5, 2016. The 50-Day Moving Average price is $18.32 and the 200 Day Moving Average price is recorded at $15.14.
Stocks of Supernus Pharmaceuticals (NASDAQ:SUPN) rallied by 3.48% during the past week but lost 3.71% on a 4-week basis. The company has outperformed the S&P 500 by 5.2% in the past week but underperformed the index by 0.79% in the last 4 weeks.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.